Pulse Biosciences (NASDAQ:PLSE) vs. Spectral AI (NASDAQ:MDAI) Financial Survey

Spectral AI (NASDAQ:MDAI) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Profitability

This table compares Spectral AI and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Pulse Biosciences	N/A	-96.89%	-74.83%

Earnings and Valuation

This table compares Spectral AI and Pulse Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$22.53 million	1.22	-$20.85 million	($1.34)	-1.10
Pulse Biosciences	$700,000.00	1,447.41	-$42.21 million	N/A	N/A

Spectral AI has higher revenue and earnings than Pulse Biosciences.

Insider & Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Spectral AI and Pulse Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Pulse Biosciences	0	0	0	0	N/A

Spectral AI currently has a consensus target price of $4.50, suggesting a potential upside of 204.05%. Given Spectral AI’s higher possible upside, analysts clearly believe Spectral AI is more favorable than Pulse Biosciences.

Risk and Volatility

Spectral AI has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.